DBLG2 System™ New Now on your smartphone*

The app that automatically adjusts insulin delivery.

DBLG2 runs on a compatible smartphone. Every 5 minutes, it uses readings from a compatible glucose sensor to adjust the insulin delivered by a compatible pump. For adults living with type 1 diabetes.

  1. Glucose sensorMeasures your glucose
  2. DBLG2 appCalculates the adjustment
  3. Insulin pumpDelivers insulin
Discover how DBLG2 works

*See the list of compatible smartphones.

A woman holding a smartphone displaying the DBLG2 app.
Our purpose
Our mission
Lighten the mental burden of diabetes with personalized, AI-powered solutions to improve everyday quality of life.
Across Europe
15,000+
Cumulative users of DBLG1 and DBLG2 since 2021.
User survey
> 85%
Rated their overall satisfaction 3/5 or higher.February 2025 · N = 2,169 users
Connected care
YourLoops
A comprehensive ecosystem empowering users and healthcare providers with seamless data sharing.

Who we are

Facilitating life through artificial intelligence.

Founded in 2015 in Grenoble, France, Diabeloop develops automated, personalized insulin delivery solutions powered by artificial intelligence for people living with Type 1 diabetes.

Together with healthcare professionals and users, we design technology to help lighten the daily burden of diabetes management.

Read our story

Our partner ecosystem

Insulin pumps

Glucose sensors (CGM)

Data & remote monitoring

  1. 2015

    A research vision becomes a company

    Diabeloop is founded by Dr. Guillaume Charpentier and Erik Huneker.

  2. 2018

    First CE marking for DBLG1

    A key step towards bringing automated insulin delivery to people living with Type 1 diabetes in Europe.

  3. 2021

    From research to everyday life

    DBLG1 launches commercially in several European countries, with Roche’s Accu-Chek Insight insulin pump.

  4. 2022

    €70 million to move forward

    A third funding round supports Diabeloop’s international development.

  5. 2023

    DBLG1 meets Kaleido

    The system launches with the Kaleido insulin pump in Germany, the Netherlands and France.

  6. 2024

    European regulatory milestone

    MDR certification

    DBLG1 with Kaleido and the YourLoops data management platform obtain certification under the European Medical Device Regulation.

    Company timeline
  7. 2025

    Two regulatory milestones for DBLG2

    CE marking & FDA clearance

    Europe

    CE marking under MDR

    DBLG2 System receives CE marking under the European Medical Device Regulation (EU) 2017/745.

    CE marking announcement (FR)

    United States

    FDA 510(k) clearance

    DBLG2 receives FDA clearance as an Interoperable Automated Glycemic Controller (iAGC).

    FDA record · K251152
  8. 2026

    DBLG2 with Kaleido & Dexcom G7

    · European rollout announced

    The launch announcement covers Germany and the Netherlands, with first commercial deliveries planned for later that summer.

    May announcement

    · Prescriptions open

    Diabeloop announces that the system is open for prescription in Germany and the Netherlands.

    July announcement
  9. 2026+Looking ahead

    The story continues

    Continuing our research and development to expand access and explore new possibilities in diabetes management.

Our products

Technology.
With you in mind.

NewNow available on Android smartphones

Automated insulin delivery app

DBLG2 System™

Running on a compatible smartphone, DBLG2 uses readings from your compatible glucose sensor to automatically adjust insulin delivery from your compatible pump.

  • Compatible sensor
  • Compatible pump
Explore DBLG2
DBLG2 app home screen on an Android smartphone, showing glucose readings and active insulin.

Data & connection

YourLoops

Your diabetes data, brought together. Review your information and share it with your healthcare team.

  • Glucose, insulin and daily events
  • Sharing with your care team
  • Access through web browser or mobile phone
YourLoops dashboard displayed on a laptop.
Access YourLoops
Dedicated handset

DBLG1 System™

Our first automated insulin delivery system, with the algorithm running on a dedicated handset.

Explore DBLG1
Useful resources

Guides & support

Find the user guide and instructions for use for your system.

Find your guide

News & perspectives

Latest news

All news

Company milestones

Awards & recognition

  • 2022

    Lauréat i-Nov

  • 2022

    Prix des internautes

    Festi Com Santé

  • 2020

    Trophée Coup de Cœur

    Présences

  • 2020

    French Tech 120

  • 2019

    Prix Start-up de l’année

    EY

  • 2019

    Lauréat du prix InnovEIT

  • 2016–2020

    Lauréat d’un programme de financements

    EIT Health

  • Trophée de l’Embarqué

    Santé

  • 2018

    Prix Born Global

    Start-up de l’année · EY

  • 2018

    Prix du Jury

    Start-up de l’année · SNITEM

  • 2018

    Prix Samsung Intelligence Artificielle

    VivaTech

DBLG2 Demo App · Interactive simulation

Get a feel
for DBLG2.

Discover the interface, explore the screens and try simulated features on your smartphone.

Download on Google Play Contact us

For Android smartphones.
Available in Germany and the Netherlands.

On a computer?Scan this code with your Android smartphone.

DBLG2 Demo Home screen showing simulated glucose data.DBLG2 Demo System screen with a virtual pump and glucose sensor.
Demo only

The DBLG2 Demo app is not a medical device. This application is for demonstration and training purposes only. It must not be used to make therapeutic decisions.